** Shares of Oxford Biodynamics OBD.L slump as much as 40%
to a record low of 2.20p, stock top pct loser across London
** The precision clinical diagnostics co begins review of
strategic options to cut costs and maximise cash runway
** OBD will explore funding options and consider
licensing or sale of assets or possible hive-off of U.S.
business into separately funded entity
** Co says will require additional cash resources by early
Q1 of 2025
** Stock at session low as of 0743 GMT, taking YTD losses to
~92%
(Reporting by Aby Jose Koilparambil in Bengaluru)
((abyjose.koilparambil@thomsonreuters.com))